See more : Bosideng International Holdings Limited (BSDGF) Income Statement Analysis – Financial Results
Complete financial analysis of Appili Therapeutics Inc. (APLIF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Appili Therapeutics Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Tri-County Financial Group, Inc. (TYFG) Income Statement Analysis – Financial Results
- MediaCo Holding Inc. (MDIA) Income Statement Analysis – Financial Results
- CEL-SCI Corporation (CVM) Income Statement Analysis – Financial Results
- The Hyakugo Bank, Ltd. (8368.T) Income Statement Analysis – Financial Results
- HAESUNG DS Co., Ltd. (195870.KS) Income Statement Analysis – Financial Results
Appili Therapeutics Inc. (APLIF)
About Appili Therapeutics Inc.
Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in the infectious disease in Canada. Its anti-infective portfolio includes Favipiravir for pandemic influenza and COVID-19; ATI-2307, an antifungal candidate, which is in clinical stage for the treatment of cryptococcal meningitis and invasive candidiasis; ATI-1503 that develops a class of gram-negative targeting antibiotics; ATI-1501, a taste-masked liquid oral suspension formulation of an antibiotic, metronidazole; ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis; and ATI-1701 is a live-attenuated vaccine for Francisella tularensis. The company has a strategic alliance with AiPharma Global Holdings LLC for the development of Avigan/Reeqonus (favipiravir). Appili Therapeutics Inc. was incorporated in 2015 and is headquartered in Halifax, Canada.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 827.41K | 1.39M | 1.39M | 0.00 | 199.11K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 13.66K | 6.27K | 0.00 | 14.84K | 0.00 | 20.71K | 17.67K | 10.51K |
| Gross Profit | 813.75K | 1.38M | 1.39M | -14.84K | 199.11K | -20.71K | -17.67K | -10.51K |
| Gross Profit Ratio | 98.35% | 99.55% | 100.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 5.62M | 21.46M | 10.87M | 11.49M | 4.18M | 3.93M | 4.95M | 2.52M |
| General & Administrative | 3.05M | 4.56M | 4.79M | 4.79M | 2.36M | 2.36M | 1.61M | 1.24M |
| Selling & Marketing | 0.00 | 185.84K | 711.93K | 2.32K | 942.40K | 861.45K | 735.00K | -5.37K |
| SG&A | 3.05M | 4.56M | 4.79M | 4.79M | 2.36M | 3.22M | 1.61M | 1.24M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 827.41K | 24.95M | 14.37M | 16.28M | 4.37M | 7.14M | 3.77M | 3.76M |
| Cost & Expenses | 8.88M | 24.95M | 14.37M | 16.30M | 4.37M | 7.16M | 3.77M | 3.77M |
| Interest Income | 16.81K | 33.73K | 116.95K | 116.95K | 40.17K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.63M | 1.55M | 69.84K | 69.84K | 12.11K | 0.00 | 208.70K | 0.00 |
| Depreciation & Amortization | 13.66K | 6.27K | 12.64K | 14.84K | 17.75K | 20.71K | 17.67K | 10.51K |
| EBITDA | -2.07M | -7.91M | -24.67M | -15.65M | -5.39M | -6.52M | -6.54M | -3.22M |
| EBITDA Ratio | -249.78% | -1,690.70% | -1,023.99% | 0.00% | -2,185.64% | 0.00% | 0.00% | 0.00% |
| Operating Income | -8.05M | -23.52M | -14.26M | -16.30M | -4.37M | -7.16M | -3.77M | -3.77M |
| Operating Income Ratio | -972.94% | -1,691.61% | -1,025.06% | 0.00% | -2,196.05% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 4.34M | -1.29M | -401.36K | 706.93K | 28.06K | 2.21M | 2.58M | 1.47M |
| Income Before Tax | -3.71M | -25.08M | -14.33M | -14.95M | -4.33M | -4.95M | -3.98M | -2.30M |
| Income Before Tax Ratio | -448.55% | -1,803.42% | -1,030.08% | 0.00% | -2,175.22% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 69.58K | 38.46K | 38.46K | -627.89K | -243.43K | -621.61K | -46.18K | -541.51K |
| Net Income | -3.78M | -25.12M | -14.33M | -14.33M | -4.33M | -4.33M | -3.98M | -1.75M |
| Net Income Ratio | -456.96% | -1,806.18% | -1,030.08% | 0.00% | -2,175.22% | 0.00% | 0.00% | 0.00% |
| EPS | -0.03 | -0.22 | -0.21 | -0.24 | -0.13 | -0.14 | -0.12 | -0.06 |
| EPS Diluted | -0.03 | -0.22 | -0.21 | -0.24 | -0.13 | -0.14 | -0.12 | -0.06 |
| Weighted Avg Shares Out | 121.27M | 113.73M | 66.73M | 59.18M | 34.33M | 30.28M | 33.54M | 30.28M |
| Weighted Avg Shares Out (Dil) | 121.27M | 113.73M | 66.73M | 59.18M | 34.33M | 30.28M | 33.54M | 30.28M |
Appili Therapeutics Inc. Expands PRESECO Clinical Trial of Avigan®/Reeqonus™ for Mild-to-Moderate COVID-19 Patients into Mexico and Brazil
Independent Data Safety Monitoring Board Recommends Appili Therapeutics Complete Its Phase 3 Avigan®/Reeqonus™ Trial for Mild-to-Moderate COVID-19 Patients
Appili Therapeutics to Present at the Bloom Burton & Co. Healthcare Investor Virtual Conference on Wednesday, April 21st, 2021
Appili Therapeutics to Participate in M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference on Friday, March 19th
Appili Therapeutics to Present as Part of Canada's Top Three Pitches at Biocom's Global Life Science Partnering Conference Today
Appili Therapeutics Appoints Veteran Healthcare Executive Rochelle Stenzler to its Board of Directors
Source: https://incomestatements.info
Category: Stock Reports